3 Stocks Worth Tracking Now: Imunon (IMNN), Enveric Biosciences (ENVB), Cardiol Therapeutics (CRDL)

As innovation in the healthcare industry accelerates, biotech companies developing next-generation therapies are gaining increased attention from both investors and analysts. Clinical advancements, regulatory momentum, and evolving treatment approaches continue to play a key role in determining the sector’s long-term outlook.

Imunon Inc (IMNN)

Imunon Inc (NASDAQ: IMNN) opened the trading on May 27, 2026, with great promise as it jumped 4.55% to $2.3. During the day, the stock rose to $2.36 and sank to $2.23. Taking a more long-term approach, IMNN posted a 52-week range of $2.08-$41.22.

The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 44.66%. Meanwhile, its Annual Earnings per share during the time was 44.66%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 50.88%. This publicly-traded company’s shares outstanding now amount to $4.20 million, simultaneously with a float of $4.09 million. The organization now has a market capitalization of $9.66 million.

Enveric Biosciences Inc (ENVB)

Enveric Biosciences Inc (NASDAQ: ENVB) started the day on May 27, 2026, with a price decrease of -4.04% at $2.14. During the day, the stock rose to $2.24 and sank to $2.13. Taking a more long-term approach, ENVB posted a 52-week range of $1.71-$17.64.

It was noted that the giant of the Healthcare sector posted annual sales growth of 67.96% over the last 5 years. Meanwhile, its Annual Earnings per share during the time was 67.96%.  This publicly-traded company’s shares outstanding now amount to $3.68 million, simultaneously with a float of $3.55 million. The organization now has a market capitalization of $7.88 million.

Cardiol Therapeutics Inc. (CRDL)

Cardiol Therapeutics Inc. (NASDAQ: CRDL) is continuing to build a broader cardiovascular growth strategy through the development of next-generation therapies aimed at large and underserved disease markets. By expanding beyond recurrent pericarditis, the company is positioning itself to address chronic cardiac conditions where inflammation and fibrosis contribute significantly to disease progression.

Market Momentum

As of May 27, 2026, CRDL closed at $1.28, down 1.54%, with trading volume of 330,143 shares compared to an average volume of 689,388 shares. The company currently maintains a market capitalization of $147.548M and a beta of 0.43, reflecting relatively moderate volatility for a small-cap biotech company. Shares continue trading within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.29 suggests substantial upside potential tied to future pipeline advancement and clinical milestones.

Pipeline Development: CRD-38

Cardiol is developing CRD-38, a proprietary subcutaneous therapy designed to improve dosing convenience while expanding applicability into broader cardiovascular indications, including heart failure. The therapy is intended to target inflammation and fibrosis, biological mechanisms strongly associated with worsening cardiac function and progressive heart disease.

Large Market Opportunity

Heart failure remains one of the largest cardiovascular markets globally, affecting millions of patients and generating substantial healthcare costs annually. Despite multiple approved therapies, unmet need persists for treatments capable of directly addressing inflammatory and fibrotic pathways associated with disease progression and long-term cardiac decline.

Outlook

As CRD-38 advances toward future clinical development, the program could emerge as an important secondary value driver for Cardiol. Continued progress across the broader pipeline may strengthen the company’s strategic positioning within cardiovascular biotechnology.